Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF(V600E)-mutated melanoma Meeting Abstract
| Authors: | Chapman, P. B.; Hauschild, A.; Robert, C.; Larkin, J. M. G.; Haanen, J. B. A. G.; Ribas, A.; Hogg, D.; Hamid, O.; Ascierto, P. A.; Testori, A.; Lorigan, P.; Dummer, R.; Sosman, J. A.; Garbe, C.; Maio, M.; Nolop, K. B.; Nelson, B. J.; Joe, A. K.; Flaherty, K. T.; McArthur, G. A. |
| Abstract Title: | Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF(V600E)-mutated melanoma |
| Meeting Title: | 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 30 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2012 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2012-05-20 |
| Language: | English |
| ACCESSION: | WOS:000318009800505 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2012.30.15_suppl.8502 |
| Notes: | Meeting Abstract: 8502^ -- Source: Wos |
